These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17263181)

  • 21. PDA PAC iAM 2017 Survey on Post Approval Change: Is the Regulatory Environment Hindering Much-Needed Innovation in the Pharma Industry?
    ; Ramnarine E; Busse U; Colao M; Edwards J; Follman K; Gale K; Good K; Kiani S; Jornitz M; Munk M; O'Donnel K; Seymour M; Simianu M; Skeens L; Vinther A; Baker D; Levy R
    PDA J Pharm Sci Technol; 2017; 71(5):421-427. PubMed ID: 28819050
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug licensing. AHF chides new WHO chief over drug licensing.
    AIDS Policy Law; 2007 Feb; 22(4):9. PubMed ID: 17375420
    [No Abstract]   [Full Text] [Related]  

  • 23. A knowledge management system for new drug submission by pharma-industries.
    Pinciroli F; Mottadelli S; Vinci M; Fabbro L; Gothager K
    Stud Health Technol Inform; 2004; 107(Pt 1):241-5. PubMed ID: 15360811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharma goes to the laundry: Public relations and the business of medical education.
    Elliott C
    Hastings Cent Rep; 2004; 34(5):18-23. PubMed ID: 15553394
    [No Abstract]   [Full Text] [Related]  

  • 25. Out-licensing role reversal.
    Morrison C
    Nat Rev Drug Discov; 2017 Mar; 16(3):151-152. PubMed ID: 28248940
    [No Abstract]   [Full Text] [Related]  

  • 26. The costs and economics of modern vaccine development.
    Batson A
    Dev Biol (Basel); 2002; 110():15-24. PubMed ID: 12477302
    [No Abstract]   [Full Text] [Related]  

  • 27. Big pharma slims down to bolster productivity.
    Owens J
    Nat Rev Drug Discov; 2007 Mar; 6(3):173-4. PubMed ID: 17396286
    [No Abstract]   [Full Text] [Related]  

  • 28. Is it too late to save Schering?
    Simons J
    Fortune; 2003 Sep; 148(5):145-6, 148, 150. PubMed ID: 14509911
    [No Abstract]   [Full Text] [Related]  

  • 29. Market-based licensing for HPV vaccines in developing countries.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 31. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA user fees and innovation.
    Somberg J
    Am J Ther; 2008; 15(2):97. PubMed ID: 18356626
    [No Abstract]   [Full Text] [Related]  

  • 33. Building for big pharma.
    Giniatullina A; Boorsma M; Mulder GJ; van Deventer S
    Nat Biotechnol; 2013 Apr; 31(4):284-7. PubMed ID: 23563416
    [No Abstract]   [Full Text] [Related]  

  • 34. US pharma company fined 435 million dollars.
    McLaughlin P
    CMAJ; 2006 Oct; 175(9):1046. PubMed ID: 17060646
    [No Abstract]   [Full Text] [Related]  

  • 35. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

  • 36. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.
    Shumoogam J; Al-Shamahi A
    IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Big pharma under the spotlight.
    Farham B
    S Afr Med J; 2013 May; 103(6):352. PubMed ID: 23725968
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharma Law Europe - Eighth Annual Conference.
    Indraccolo AD; Chapman C
    IDrugs; 2008 Nov; 11(11):807-10. PubMed ID: 18988124
    [No Abstract]   [Full Text] [Related]  

  • 39. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conditional licensing of veterinary biologicals in the United States: a major manufacturer's perspective.
    Carlson MM; Chiang YW; Chu HJ
    Dev Biol (Basel); 2004; 117():97-103. PubMed ID: 15597624
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.